Aeglea BioTherapeutics Email Format

Biotechnology ResearchTexas, United States51-200 Employees

With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.

For more information, please visit http://aeglea.com.

✕

Access Insights for Aeglea BioTherapeutics and Millions of Other Companies

Sign up for full access to Aeglea BioTherapeutics information.

Continue with GoogleContinue with Microsoft

No credit card needed

OR

Work email

Create AccountBy creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Sign up for free to view info

Company overview Employee directory